Federal enforcement against CBD medical claims in the US is going strong, with the Federal Trade Commission (FTC) recently sending a warning letter to a new company about what it said were prohibited medical claims
...
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.